Home Page >
News and press releases >
News archive >
QUARTZ passes 300 patient milestone
QUARTZ passes 300 patient milestone
6 December 2011
QUARTZ
(Quality of life after treatment for brain metastases) has now
randomised 310 patients out of the target 534. Despite widespread support and a
very active Trial Management Group (TMG), recruitment remained
slower than anticipated, so this milestone represents an important
achievement for all those involved in the trial.
This trial looks to answer a vital clinical question by
assessing the value of treating patients with inoperable brain
metastases from non-small cell lung cancer (NSCLC) with whole brain
radiotherapy (WBRT), in addition to treatment with optimal
supportive care and steroids.
A potential recruitment barrier was thought to be the lack of
any preliminary data from phase II trials suggesting the omission
of WBRT is not detrimental to patients. The unusual step was therefore
made to analyse and release data from the first 151 patients
randomised to the trial.
The interim data suggested that omitting WBRT is not detrimental
in the treatment of patients with inoperable brain metastases from
non-small cell lung cancer. Although not conclusive, the data
support the need for the trial to investigate the appropriate use
of WBRT in this patient population. Presentations describing the
interim results can be accessed using the links below.
The results from analyses of these 151 patients’ data confirm
the need for the trial to continue. It is aimed for the trial to
close to recruitment in September 2013 with final results in
December 2013.
Further Information
